Eli Lilly shares tumbled Friday after regulators said they needed more data on the company’s filing for fast-track approval of its potential Alzheimer’s treatment.
Read Also :
V4 News For You
Stay informed and read the latest news today from The Associated Press, the definitive source for independent journalism from every corner of the globe.